Procept Biorobotics (PRCT) Stock

PROCEPT BioRobotics (PRCT) develops and commercialises a minimally invasive robotic system for treating benign prostatic hyperplasia (BPH). Its flagship Aquablation therapy uses a precision waterjet and real-time imaging to remove prostate tissue, positioning the company in the specialised urology devices niche. Investors should know the business model leans on system sales plus recurring consumable and service revenue as clinical adoption grows. Growth drivers include expanding procedure volumes, broader clinical evidence, international regulatory approvals and increased installed base. Key risks are adoption hurdles versus established surgical approaches and drugs, reimbursement pressures, execution on commercial expansion, and the possibility of variable procedure volumes. As a smaller-cap medical device company (market cap roughly $1.9bn), PRCT can be more volatile than large healthcare names and may need ongoing investment to scale. This is general educational information — not personalised investment advice — and potential investors should consider how such a stock fits their risk tolerance and portfolio goals.